摘要
目的:探讨吡多胺(pyridoxamine,PM)对早期糖基化产物(Amadori产物)生成的干预作用。方法:在δ-葡萄糖酸内酯(δ-Glu)和血标本中分别加入不同浓度的PM(10,25,50,100mmol·L-1),以氨基胍(aminoguanidine,AG)作为阳性对照,37℃水浴16h。应用全自动糖化血红蛋白批量检测仪构建的低压离子交换层析梯度洗脱分析系统测定其糖基化血红蛋白A1c(HbA1c)水平。结果:δ-Glu组HbA1c水平较基线对照组明显增高(P<0.01)。25,50,100mmol·L-1 PM组HbA1c水平明显低于δ-Glu组(P<0.05和P<0.01)。结论:PM能抑制Amadori产物的生成。
Objective:To study the effect of pyridoxamine (PM) on the product(Amadori) in the early stage of glycosylation. Methods: This assay was based on the interaction of δ-gluconolactone (δ-Glu) ,an oxidized(ketoaldehyde)anologue of glucose, with hemoglobin present in blood samples. PM solution of different concentrations (10,25,50, l00mmol·L-1) was added δ-Glu and blood samples, and heated in water bath at 37℃ for 16h. The glycosylated hemoglobin (HbA1c) was determined by low pressure cation exchange chromatography in conjunction with gradient elution system. Results:The HbA1c levels in δ-Glu-treated blood group were higher than those of control group (P<0.01). PM group (25,50,100mmol·L-1) or AG group were distinctly decreased in HbA1c levels as compared with those of δ-Glu-treated blood (P<0.05 and P < 0. 01), except for 10 mmol·L-1 PM group (P>.05).Conclusion:PM can inhibit the formation of Amadori product.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2004年第4期317-319,共3页
Chinese Journal of New Drugs
基金
吉林省科学技术厅资助项目(20010545)
关键词
吡多胺
氨基胍
糖基化血红蛋白
δ-葡萄糖酸内酯
低压离子交换层析梯度洗脱分析系统
pyridoxamine
aminoguanidine
glycosylated hemoglobin
δ-gluconolactone
low pressure cation exchange chromatography in conjunction with gradient elution system
